Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial
ConclusionsThe PLINY THE ELDER trial will determine whether a lower dose of ticagrelor confers non-inferior platelet inhibition compared with the standard dose in the early phase of ACS among elderly patients undergoing PCI, informing future clinical investigation.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Angioplasty | Aspirin | Bleeding | Cardiology | Cardiovascular | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Study